Literaturverzeichnis


7. Andrews PLR, Davidson HIM. Activation of vagal afferent terminals by 5-hydroxytryptamine is mediated by the 5-HT3-receptor in the anaesthetized ferret. J Physiol 1990; 422: 92 P


14 Aynacioglu AS; Sachse C; Bozkurt A et al. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. Clin Pharmacol 1999; 66: 185–92

15 Bathum L, Johansson I, Ingelman-Sundberg M, Horder M, Brosen K. Ultrarapid metabolism of sparteine: frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by restriction fragment length polymorphism and long polymerase chain reaction. Pharmacogenetics 1998; 8: 119–23


23 Blower PR. 5-HT3 receptor antagonists and the cytochrome P450 system – clinical implications. Cancer 2000; 8: 405-14


32 Corrigan BW, Nicholls B, Thakrai B. Heterogeneity in systemic availability of ondansetron and granisetron following oral administration. Drug Metab Dispos 1999; 27: 110–12


38 Daly AK, Brockmöller J, Broly F et al. Nomenclature for human CYP2D6 alleles Pharmacogenetics 1996; 6: 193–201


40 Daly AK, Leathart JB, London SJ, Idle JR. An inactive cytochrome P450 (CYP2D6) allele containing a deletion and a base substitution. Hum Genet 1995; 95 (3): 337 -41


42 De Bruijn KM. The development of tropisetron in its clinical perspective. Ann Oncol 1993; 4: 19–23


45 Dixon CM, Colthup PV, Serabit-Singh CJ, Kerr BM, Boehlert CC, Park GR, Tarbit MH. Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. Drug Metab Dispos 1995; 23: 1225-30


49 Evans WE, Relling MV. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratios to discriminate reliably heterozygous and homozygous extensive metabolizers. Pharmacogenetics 1991; 1 (3):143-48


54 Fischer V, Baldeck JP, Tse FL. Pharmacokinetics and metabolism of the 5-hydroxytryptamine antagonist tropisetron after single oral doses in humans. Drug Metab Dispos 1992; 20: 603-07


59 Fukui HM, Yamamoto T, Ando S, Sasaki S, Sato S. Increase in serotonin levels in the dog ileum and blood by cisplatin as measured by microdialysis. Neuropharmacology 1993; 32: 959-68


64 Gralla RJ. Current issues in the management of nausea and vomiting. Ann Oncol 1993; 4 (Suppl.3): S3-S7


70 Griese EK, Zanger UM, Brudermans U et al. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 1998; 8: 15-26

71 Guzey C, Norstrom A, Spigset O. Change from the CYP2D6 extensive metabolizer to the poor metabolizer phenotype during treatment with bupropion. Ther Drug Monit 2002; 24 (3): 436–37


73 Harris RZ, Benet LZ, Schwarz JB. Gender effects in pharmacokinetics and pharmacodynamics. Drugs 1995; 50: 222–39


77 Hesketh PJ. Potential role of the NK1 receptor antagonists in chemotherapy-induced nausea and vomiting. Support Care Cancer 2001; 9: 350-54


85 Italian Group for Antiemetic Research: Dexamethasone alone or combined with ondansetron in the prevention of delayed nausea and vomiting induced by chemotherapy. N Engl J Med 2000; 342: 1554-59


87 Johansson I, Oscarsson M, Yue QY, Bertilsson F, Sjöqvist F, Ingelman-Sundberg M. Genetic analysis of the Chinese cytochrome P450D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 1994; 46: 452-59 (Abstract)


93 Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzalez FJ. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and isolation of the polymorphic CYP2D6 gene, a related gene and a pseudogene. Amer J Human Genet 1989; 45: 889-904


95 Kris MG, Radford JE, Pizzo BA, Inabinet R, Hesketh A, Hesketh PJ. Use of NK1 receptor antagonist to prevent delayed emesis after cisplatin. J Natl Canc Inst 1997; 89 817-18

96 Kris MG, Roila F, De Mulder PHM, Marty M. Review article: Delayed emesis following anticancer chemotherapy. Supportive Care Cancer Abstract Volume 1998; 6: 228-32


102 Lundqvist E, Johansson I, Ingelman-Sundberg M. Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 gene. Gene 1999; 226: 327-38


104 Marez D, Legrand M, Sabbagh N, Lo-Guidice JM, Boone P, Broly F. An additional allelic variant of the CYP2D6 gene causing impaired metabolism of sparteine. Hum Genet 1996; 97: 668-70


108 Mc Elroy S, Sachse C, Brockmöller J et al. CYP2D6 genotyping as an alternative to phenotyping for determination of metabolic status in a clinical trial setting. AAPS Pharm Sci 2000; 2: E33


115 Morrow GR, Hickok JT, Rosenthal SN. Progress in reducing nausea and emesis. Comparisons of ondansetron (zofran), granisetron (kytril) and tropisetron (navoban) Cancer 1995; 76: 343-57


119 Navoban Product Information; Novartis Pharma, Basel, Switzerland


125 Rademaker M. Do women have more adverse drug reactions? Am J Clin Dermatol 2001; 2: 349–51


128 Roila F, Palladino MA, Ciccarese G, Basurto C. Recent improvements in antiemetic therapy. Tumori 1993; 83 (Suppl.2): S3-S14


132 Sachse C, Brockmöller J, Bauer S, Reum T, Roots I. A rare insertion of T 226 in exon 1 of CYP2D6 causes a frameshift and is associated with the poor metabolizer phenotype : CYP2D6*15. Pharmacogenetics 1996; 6 (3): 269-72


134 Sachse C, Brockmöller J, Hildebrand M, Muller K, Roots I. Correctness of prediction of the CYP2D6 phenotype confirmed by genotyping 47 intermediate and poor metabolizers of debrisoquine. Pharmacogenetics 1998; 8: 181–85
135 Sanwald P, David M, Dow J. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Comparison with other indole-containing 5-HT3 antagonists. Drug Metab Dispos 1996; 24: 603-09


137 Schwörer K, Racke K, Kilbinger H. Cisplatin increases the release of 5-hydroxytryptamine (5–HT) from the isolated vascularity perfused small intestine of the guinea-pig : involvement of 5-HT3 receptors. Naunyn Schmiedeberg’s Arch Pharmacol 1991; 344: 143-49


148 Tonato M, Roila F, Del Favero A. Are there differences among the serotonin antagonists? Support Care Cancer 1994; 2: 293-96


154 Waldvogel HH. Antiemetische Therapie. Thieme-Verlag Stuttgart 1995


